Ultragenyx (RARE) Shares Plunge 45% Following Critical Drug Trial Failure

Ultragenyx (RARE) stock plunged 45% after apazunersen missed Phase 3 trial endpoints for Angelman syndrome, raising concerns about future programs.

The post Ultragenyx (RARE) Shares Plunge 45% Following Critical Drug Trial Failure appeared first on Blockonomi.